Oligonucleotide Players

Chapter 1: Market And Technology Overview

• Introduction and scope
• A primer on DNA, RNA and the mechanism of antisense action
• Therapeutic applications of antisense
• Review of oligonucleotide chemistries
• First-generation oligonucleotides
• Second-generation oligonucleotides
• Third-generation oligonucleotides
• Novel types of oligonucleotide
• Gene-targeting oligonucleotides
• Protein-targeting oligonucleotides
• Ribozymes and other catalytic oligonucleotides
• Delivery of oligonucleotides
• Enhancement of stability and cellular uptake
• Targeted delivery
• Noninvasive delivery
• Antisense oligonucleotides under commercial investigation
• Highlights from clinical trials
• Three generations of antisense products
• Various antisense oligonucleotides
• Other oligonucleotides under commercial investigation
• Oligonucleotides with antiviral properties
• Oligonucleotides with specific properties
• Protein-binding oligonucleotides

Chapter 2: Company Profiles

• List of companies profiled
• Amgen Inc.
• Angiogene Inc.
• Antisoma PLC
• Aronex Pharmaceuticals Inc.
• Atlantic Pharmaceuticals Inc.
• AVI BioPharma Inc.
• Baxter International
• BioResearch Ireland
• Biovector Therapeutics SA
• Boehringer Ingelheim GmbH
• Boron Biologicals Inc.
• Bristol-Myers Squibb Company
• Chemo-Sero-Therapeutic Research Institute
• Chiron Corporation
• Chugai Pharmaceutical Company Ltd
• Crinos Industria Farmacobiologica SPA
• Cryogenic Solutions Inc.
• CV Therapeutics Inc.
• DanBioSyst UK Ltd
• DepoTech Corporation
• Epoch Pharmaceuticals Inc.
• GeneSense Technologies Inc.
• Genset
• Genta Inc.
• Genzyme Corporation
• Geron Corporation
• Gilead Sciences Inc.
• Glaxo Wellcome PLC
• Hesed Biomed Inc.
• Hoechst AG
• Human Genome Sciences Inc.
• Hybridon Inc.
• ICN Pharmaceuticals Inc.
• Immune Response Corporation
• Incyte Pharmaceuticals Inc.
• Inex Pharmaceuticals Corporation
• Inkine Pharmaceutical Company Inc.
• Innovir Laboratories Inc.
• Intercardia Inc.
• Iomed Inc.
• Isis Pharmaceuticals Inc.
• Kimeragen Inc.
• Lynx Therapeutics Inc.
• Medtronic
• Methyl-Gene Inc.
• NeoPharm Inc.
• NeXstar Pharmaceuticals Inc.
• Novartis AG
• NovoPharm Biotech Inc.
• Oligo Therapeutics Inc.
• Oncor Inc.
• Pantheco A/S
• Ribozyme Pharmaceuticals Inc.
• Sankyo Company Ltd
• Sequus Pharmaceuticals Inc.
• Somagenics Inc.
• SRC VB Vector
• Supratek Pharma Inc.
• Synsorb Biotech Inc.
• Targeted Genetics Corporation
• Theratechnologies Inc.
• Vical Inc.
• VIMRx Pharmaceuticals Inc.
• Zynaxis Inc.

Chapter 3: Financial And Market Analyses

• Markets for oligonucleotide therapeutics
• AIDS and related conditions
• Gastroenterology
• Cancer
• Dermatology
• Immunology
• Musculoskeletal disorders
• Ophthalmology
• Deep vein thrombosis
• Other indications
• Market forecast
• Oligonucleotide company league tables

Chapter 4: Trends And Opportunities

• Antisense therapeutics - an area of opportunity
• Third-generation oligonucleotides - cheaper yet better
• New perspectives in delivery of oligonucleotides
• Prospects for large-scale oligonucleotide synthesis
• Applications of antisense to drug and gene target validation
• Oligonucleotide strategies not based on antisense
• Patent analysis
• Assignee organisations

List Of Tables
Table 1.1: Oligonucleotide chemistries
Table 1.2: Novel types of oligonucleotide
Table 1.3: Oligonucleotide delivery systems
Table 1.4: Three generations of antisense oligonucleotides
Table 1.5: Antisense oligonucleotides (various)
Table 1.6: Oligonucleotides not based on antisense
Table 2.1: Amgen - financial data 1996-98
Table 2.2: Aronex Pharmaceuticals - financial data 1995-97
Table 2.3: Atlantic Pharmaceuticals - financial data 1996-98
Table 2.4: AVI BioPharma - financial data 1996-97
Table 2.5: Baxter International - financial data 1996-98
Table 2.6: Boehringer Ingelheim - financial data 1996-97
Table 2.7: Bristol-Myers Squibb - financial data 1996-98
Table 2.8: Chemo-Sero-Therapeutic Research Institute - financial information
Table 2.9: Chiron - financial data 1995-97
Table 2.10: Chugai Pharmaceutical - financial data 1996-98
Table 2.11: CV Therapeutics - financial data 1996-97
Table 2.12: Epoch Pharmaceuticals - financial data 1995-97
Table 2.13: Genset - financial data 1996-97
Table 2.14: Genta - financial data 1995-97
Table 2.15: Genzyme - financial data 1995-97
Table 2.16: Geron - financial data 1996-97
Table 2.17: Gilead Sciences - financial data 1996-98
Table 2.18: Glaxo Wellcome - financial data 1995-97
Table 2.19: Hoechst AG - financial data 1997
Table 2.20: Hoechst Marion Roussel - financial data 1996-97
Table 2.21: Human Genome Sciences - financial data 1995-97
Table 2.22: Hybridon - financial data 1995-97
Table 2.23: ICN Pharmaceuticals - financial data 1995-97
Table 2.24: Immune Response - financial data 1995-97
Table 2.25: Incyte Pharmaceuticals - financial data 1995-97
Table 2.26: Inex Pharmaceuticals - financial data 1996-97
Table 2.27: Inkine Pharmaceutical - financial data 1996-98
Table 2.28: Innovir Laboratories - financial data 1995-97
Table 2.29: Intercardia - financial data 1996-98
Table 2.30: Iomed - financial data 1997-98
Table 2.31: Isis Pharmaceuticals - financial data 1995-97
Table 2.32: Lynx Therapeutics - financial data 1997
Table 2.33: Medtronic - financial data 1996-98
Table 2.34: NeoPharm - financial data 1995-97
Table 2.35: NeXstar Pharmaceuticals - financial data 1995-97
Table 2.36: Novartis - financial data 1995-97
Table 2.37: NovoPharm Biotech - financial data 1996-97
Table 2.38: Oncor - financial data 1995-97
Table 2.39: Ribozyme Pharmaceuticals - financial data 1996-97
Table 2.40: Sankyo - financial data 1996-98
Table 2.41: Sequus Pharmaceuticals - financial data 1995-97
Table 2.42: Synsorb Biotech - financial data 1996-97
Table 2.43: Targeted Genetics - financial data 1995-97
Table 2.44: Vical - financial data 1995-97
Table 2.45: VIMRx Pharmaceuticals - financial data 1995-97
Table 3.1: Important clinical indications for oligonucleotide therapy
Table 3.2: World pharmaceutical market by region in 1998
Table 3.3: Sizes of oligonucleotide-related pharmaceutical markets in 1998
Table 3.4: Oligonucleotides in clinical trials
Table 3.5: Oligonucleotide therapeutics market in 1999 and 2005
Table 3.6: Top 35 companies ranked by total revenues
Table 3.7: Top 35 companies ranked by net income/loss
Table 3.8: Top 35 companies ranked by total assets
Table 3.9: Top 35 companies ranked by R&D expenditure
Table 4.1: Oligonucleotide therapeutic patents, by subject
Table 4.2: US patents concerning oligonucleotides targeted at specific genes
Table 4.3: US patents concerning modified oligonucleotides
Table 4.4: US patents concerning oligonucleotide delivery methods
Table 4.5: US oligonucleotide patents concerning general therapeutic methods
Table 4.6: Patenting activity by organisation
Table 4.7: Patent citations by organisation
Table 4.8: Top 10 patent citations in oligonucleotide therapeutics